

Sl. No.	Particulars	UNAUDITED			AUDITED	
		3 Months ended 30.09.2011	3 Months ended 30.09.2010	9 Months ended 30.09.2011	9 Months ended 30.09.2010	12 Months ended 31.12.2010
1	(a) Net Sales / Income from Operations	19,602.10	12,672.08	52,090.41	37,672.76	50,463.77
	(b) Other Operating Income	96.26	915.51	395.68	1,086.08	2,480.61
	Total Income	19,698.36	13,587.59	52,486.09	38,758.84	52,944.38
2	Expenditure	(225.41)	(471.31)	530.83	(627.12)	(785.38)
	(a) (Increase) / decrease in stock in trade and work in progress	9,872.00	6,877.57	21,959.14	17,482.59	23,693.57
	(b) Consumption of materials	3,321.60	2,082.79	9,512.95	5,085.43	6,460.56
	(c) Purchase of fixed goods	1,725.07	1,104.72	4,807.48	3,743.53	5,255.12
	(d) Employee cost	400.99	348.91	1,191.00	1,039.02	1,508.21
	(e) Depreciation	4,454.36	1,927.84	8,965.64	6,033.60	8,846.32
	(f) Other Expenditure	19,548.61	11,870.52	46,967.04	32,757.05	44,978.40
	Total Expenditure	149.75	1,717.07	5,519.05	6,001.79	7,965.98
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	149.75	1,717.07	5,519.05	6,001.79	7,965.98
4	Other Income	2,083.81	2,127.29	6,012.05	5,828.16	4,207.72
5	Profit before Interest & Exceptional Items (3+4)	2,083.81	2,127.29	6,012.05	5,828.16	4,207.72
6	Interest (net)	(1,934.06)	(410.22)	(493.00)	173.63	3,758.26
7	Profit after Interest but before Exceptional Items (5-6)	(5179.35)	1,594.97	(4,798.14)	1,961.51	2,353.42
8	Exceptional Items:		(458.31)		(482.92)	944.02
	- Exchange Fluctuation (loss) / gain (Net)	93.95	338.77	1,851.77	(749.35)	(1,56.28)
	- Exchange (loss) / gain on restatement of Hedged investments				62.04	
	- Profit on sale of investment					
	- Changes in fair value of Options embedded in FCCBs					
	- Provision for diminution in value of investment reversed					
9	Profit / (Loss) from Ordinary Activities before tax (7+8)	(7,019.46)	1,065.21	(3,439.37)	964.91	8,908.17
10	Tax Expense / (credit)	(500.00)		345.00	252.08	1,552.09
11	Net Profit / (Loss) from Ordinary activities after tax (9-10)	(6,519.46)	1,065.21	(3,784.37)	712.83	7,356.08
12	Extraordinary Item					
13	Net Profit / (Loss) for the period / year (11-12)	(6,519.46)	1,065.21	(3,784.37)	712.83	7,356.08
14	Paid-up Equity Share Capital (Face value of Rs.10/-each)	5,837.42	4,692.11	5,837.42	4,692.11	5,774.47
15	Reserves excluding revaluation reserves					134,627.49
16	Earnings per Share (EPS) :					
	Basic & Diluted EPS after Extraordinary Items for the year (Rs. per share)					
	(a) Basic EPS	(11.21)	2.18	(6.53)	1.05	15.69
	(b) Diluted EPS	(11.21)	0.54	(6.53)	0.97	11.98
17	Aggregate of Public shareholding :					
	(a) Number of shares	41,779,913	30,627,765	41,779,913	30,627,765	41,401,298
	(b) Percentage of shareholding	71.57%	65.27%	71.57%	65.27%	71.70%
18	Promoters and Promoter group shareholding :					
	(a) Pledged / Encumbered	10,328,285	8,196,000	10,328,285	8,196,000	8,000,000
	- Number of shares	62.24%	50.30%	62.24%	50.30%	48.95%
	- Percentage of shareholding (as a % of the total share capital of the Company)	17.69%	17.47%	17.69%	17.47%	13.85%
	(b) Non Pledged / Non Encumbered	6,265,973	8,097,373	6,265,973	8,097,373	8,343,373
	- Number of shares	37.76%	49.70%	37.76%	49.70%	51.05%
	- Percentage of shareholding (as a % of the total share capital of the Company)	10.73%	17.26%	10.73%	17.26%	14.45%

Handwritten signature


Notes:

- 1 The above unaudited results of the Company has been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on October 24, 2011.
- 2 The Statutory Auditors have carried out limited review of the above standalone results.
- 3 Consequent to the approval of Scheme of Arrangement during the year ending December 31, 2009 by the Hon'ble High Courts of Judicature, the Company has utilised the Reserve for Business Restructure (BRB) as under:-

Particulars	Quarter Ended	Quarter Ended	Nine Months	Nine Months	Year Ended
	30.09.2011	30.09.2010	Ended 30.09.2011	Ended 30.09.2010	
Rs. in Lakhs					
Utilisation of BRB:					
- Depreciation and Amortisation	428.61	417.31	1,271.87	1,251.93	1,696.24
- Employee compensation	17.61	60.09	284.02	515.51	387.08
- Interest on Fixed Loans	450.00	-	450.00	-	911.23
- Other expenses	0.00	-	466.38	36.34	-
Realisation of assets written off earlier	-	-	(4.64)	(460.16)	(2,525.06)
Impact if the Company followed the Accounting Standards instead of the accounting treatment provided in the Scheme :-					
On Net Profit for the quarter - Decrease	896.22	477.40	2,467.63	1,343.62	469.49
Earnings / (Loss) per share (EPS) (Face value of Rs.10/-each) (Rs.)					
Basic	(12.75)	1.12	(10.78)	(2.05)	14.69
Diluted	(12.75)	(0.35)	(10.78)	(2.05)	11.18

- 4 During the nine months period, 404,500, 75,000 & 1,50,000 equity shares were allotted by the Company on exercising equal number of options under Sridas Arcolab ESOP 2008, ESOP 2008 (Directors) & 2006 Schemes respectively. Further, 9,000 options were granted to eligible employees of the Company under 2008 ESOP Scheme.
- 5 The Company had early adopted Accounting Standard (AS) 30 "Financial Instruments: Recognition and Measurement" and in the spirit of full adoption, the Company had also adopted the limited revision to other notified AS. In accordance with these provisions, certain investments which were designated in a fair value hedge relationship were restated at the period end rates. Pursuant to the notification dated February 11, 2011 issued by The Institute of Chartered Accountants of India, which clarified that the provisions of AS 30 would need to be applied only to the extent they do not contravene the other mandatory accounting standards. During the quarter ended December 31, 2010, the Company reversed such restatements done in prior quarters. The results for the quarter and nine months ended September 30, 2010 included in these results are extracted from the results published for the quarter and nine months then ended and do not incorporate the impact of the reversal of restatements referred above. The exchange gain / (loss) recognised in the quarter and nine months ended September 30, 2010 on account of such restatement was (Rs. 458.31 lakhs) and (Rs. 482.92 Lakhs) respectively.
- 6 Exchange fluctuation gain/loss (net) included under 'Exceptional Items' comprises the unrealized gains/losses arising out of the restatement of FCCBs, External Commercial Borrowings, Intra group loans given, gains/losses on forward exchange option contracts and certain foreign currency denominated monetary items.
- 7 The Company's operations fall within a single business segment viz. "Pharmaceutical Products" and as such there is no reportable segment information as per Accounting Standard 17 issued under the relevant provision of the Companies Act, 1956.
- 8 Investor grievances received and disposed off during the quarter ended September 30, 2011 :
 a) Pending complaints at the beginning of the quarter - Nil b) No. of Complaints received - 22
 c) Complaints disposed - 22 d) Complaints unresolved - Nil
- 9 The previous period's figures have been regrouped/reclassified wherever necessary to conform to current period's classification.

Bangalore, October, 24, 2011

For and on behalf of the Board

 Arun Kumar
 Vice Chairman & Managing Director